SEARCH:   Advanced

Blood, 1 April 2007, Vol. 109, No. 7, pp. 2759-2766. Prepublished online as a Blood First Edition Paper on November 28, 2006; DOI 10.1182/blood-2006-07-035709. This Article Full Text Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2006-07-035709v1 109/7/2759    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Verdonck, L. F. Articles by van Imhoff, G. W. Search for Related Content PubMed PubMed Citation Articles by Verdonck, L. F. Articles by van Imhoff, G. W. Related Collections Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) Leo F. Verdonck1, Annelise Notenboom2, Daphne D. de Jong3, Marius A. MacKenzie4, Gregor E. G. Verhoef9, Mark H. H. Kramer5, Gert J. Ossenkoppele6, Jeanette K. Doorduijn7, Pieter Sonneveld7, and Gustaaf W. van Imhoff8 1 Department of Hematology, University Medical Center, Utrecht, The Netherlands; 2 HOVON Data Center, Erasmus Medical Center, Rotterdam, The Netherlands; 3 Department of Pathology, Netherlands Cancer Institute, Amsterdam; 4 Department of Hematology, University Medical Center, Nijmegen, The Netherlands; 5 Department of Internal Medicine, Meander Medical Center, Amersfoort, The Netherlands; 6 Department of Hematology, Vrije Universiteit (VU) Medical Center, Amsterdam, The Netherlands; 7 Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands; 8 Department of Hematology, University Medical Center, Groningen, The Netherlands; 9 Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium Optimal dose and timing of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy for aggressive non-Hodgkin lymphoma (NHL) is still an unresolved issue. We assessed whether dose intensifications with cyclophosphamide and doxorubicin might improve outcome in younger patients with intermediate-risk aggressive NHL. Previously untreated patients were assigned to receive either 8 courses of standard CHOP (n = 239) or 6 courses of intensified (I)–CHOP (n = 238). Although there was a tendency in favor of I-CHOP for overall survival (OS), disease-free survival (DFS), and event-free survival (EFS), the differences were not significant. However, although these analyses were not planned, when the intermediate-risk group was divided into low-intermediate- and high-intermediate-risk patients according to the International Prognostic Index (IPI), low-intermediate-risk patients had improved 6-year OS (67% vs 52%; P = .05), DFS (58% vs 45%; P = .06), and EFS (41% vs 30%; P = .21) when they were treated with I-CHOP compared with standard CHOP. On the other hand, high-intermediate-risk patients seem to have no benefit from I-CHOP. Although clinically relevant side effects occurred more often in the I-CHOP arm, treatment-related mortality was similar. These data suggest that I-CHOP might be preferable to standard CHOP in younger patients with low-intermediate-risk aggressive NHL. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: E. Derenzini, M. P. Fina, V. Stefoni, C. Pellegrini, F. Venturini, A. Broccoli, L. Gandolfi, S. Pileri, S. Fanti, E. Lopci, et al. MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients Ann. Onc., October 27, 2009; (2009) mdp455v1. [Abstract] [Full Text] [PDF] H.A. Azim, L. Santoro, R.G. Bociek, S. Gandini, R.A. Malek, and H.A. Azim Jr High dose intensity doxorubicin in aggressive non-Hodgkin's lymphoma: a literature-based meta-analysis Ann. Onc., October 22, 2009; (2009) mdp425v1. [Abstract] [Full Text] [PDF] W. H. Wilson, K. Dunleavy, S. Pittaluga, U. Hegde, N. Grant, S. M. Steinberg, M. Raffeld, M. Gutierrez, B. A. Chabner, L. Staudt, et al. Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers J. Clin. Oncol., June 1, 2008; 26(16): 2717 - 2724. [Abstract] [Full Text] [PDF] G. P. Canellos What Constitutes "Improved Prognosis"? J. Clin. Oncol., April 20, 2008; 26(12): 1913 - 1914. [Full Text] [PDF] P. Morel, P. Gaulard, C. Gisselbrecht, C. Ferme, G. Salles, H. Tilly, J. Briere, M. C. Copin, P. Lederlin, O. Hermine, et al. Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2 Ann. Onc., March 1, 2008; 19(3): 560 - 565. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020